Q4 2025 · 13F-HR
Artia Global Partners LPholdings as filed
Filed 2026-02-17 · accession 0001937964-26-000002
$705.8M
Reported value
55
Positions
2025-12-31
Period end
The Brief · Artia Global Partners LP · Q4 2025
AI · grounded in 13F
Artia Global Partners LP closed its position in VRNA, reducing exposure by $40.4M. The fund also exited positions in 2GH and VRTX, totaling $27.9M and $21.6M in reductions respectively. On the buy side, the fund established a new position in CDTX worth $15.6M and increased its share count in VKTX by 392.1%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 457669307 | INSM | INSMED INC | $118.7M | 16.8% | 682,212 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $81.0M | 11.5% | 600,747 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $73.1M | 10.4% | 420,000 | PUT | SOLE |
| 04016X101 | ARGX | ARGENX SE | $54.4M | 7.71% | 64,699 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $54.3M | 7.69% | 50,500 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $25.3M | 3.59% | 719,365 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $25.2M | 3.57% | 2,013,602 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $24.7M | 3.50% | 533,698 | Common | SOLE |
| 74347W601 | UGL | PROSHARES TR II | $24.5M | 3.48% | 442,119 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $24.5M | 3.47% | 1,023,539 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $17.7M | 2.50% | 503,936 | Common | SOLE |
| 046353108 | AZNN | ASTRAZENECA PLC | $17.5M | 2.48% | 190,752 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $15.6M | 2.22% | 70,824 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $14.0M | 1.99% | 767,098 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $11.4M | 1.62% | 144,376 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $8.5M | 1.20% | 205,090 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $8.3M | 1.18% | 104,190 | Common | SOLE |
| 74834L100 | DGX | QUEST DIAGNOSTICS INC | $7.1M | 1.00% | 40,817 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $6.9M | 0.98% | 17,400 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $6.3M | 0.89% | 695,982 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $6.2M | 0.88% | 59,200 | Common | SOLE |
| 74347W601 | UGL | PROSHARES TR II | $5.6M | 0.79% | 100,000 | PUT | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $5.0M | 0.71% | 137,800 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $4.9M | 0.70% | 119,741 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $4.7M | 0.66% | 1,992,367 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $4.3M | 0.61% | 60,100 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $4.2M | 0.60% | 96,285 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $4.2M | 0.60% | 138,508 | Common | SOLE |
| 74291D104 | PROK | PROKIDNEY CORP | $4.1M | 0.58% | 1,838,411 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $3.8M | 0.54% | 17,740 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $3.3M | 0.47% | 14,500 | Common | SOLE |
| 07782B104 | BLTE | BELITE BIO INC | $2.9M | 0.41% | 17,989 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $2.8M | 0.40% | 129,800 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $2.7M | 0.38% | 70,700 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $2.6M | 0.37% | 33,407 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $2.4M | 0.35% | 5,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $2.3M | 0.33% | 50,000 | CALL | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $2.0M | 0.28% | 22,951 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $1.9M | 0.26% | 68,653 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $1.8M | 0.25% | 40,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $1.7M | 0.24% | 141,061 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $1.6M | 0.22% | 20,400 | Common | SOLE |
| 10950A106 | BTSG | BRIGHTSPRING HEALTH SVCS INC | $1.6M | 0.22% | 41,600 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $1.3M | 0.19% | 205,324 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $1.3M | 0.19% | 9,900 | CALL | SOLE |
| 15102K100 | CELC | CELCUITY INC | $1.3M | 0.18% | 12,900 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $1.2M | 0.17% | 29,200 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $1.0M | 0.15% | 85,200 | CALL | SOLE |
| 670703107 | NUVL | NUVALENT INC | $814,779 | 0.12% | 8,100 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $754,911 | 0.11% | 41,570 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $736,850 | 0.10% | 2,500 | Common | SOLE |
| 02157Q109 | ANRO | ALTO NEUROSCIENCE INC | $519,618 | 0.07% | 29,192 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $512,955 | 0.07% | 42,080 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $475,851 | 0.07% | 17,019 | Common | SOLE |
| 55234L204 | LYRA | LYRA THERAPEUTICS INC | $26,968 | 0.00% | 8,756 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.